… skin reactions with immune checkpoint inhibitors are non-specific maculopapular exanthemas
that resemble the ‘classic’ maculopapular drug rashes. Lichenoid drug eruption may …

… This was consistent with a drug reaction. … The most common cutaneous adverse event
triggered by EGFR inhibitors in our cohort of cases was a papulopustular rash (80%). This finding …

… Fortunately, with EGFRI therapy, severe drug eruptions such as Stevens–Johnson syndrome
(SJS) and toxic epidermal necrolysis (TEN) are exceedingly rare, but they have been …

… In case of grade 3 rash, EGFR-TKI therapy should be temporarily … EGFR-TKI for prescribing
advice [18–20, 24, 26, 27]. We recommend restarting EGFR-TKI therapy only when the rash …

… The high incidence of EGFR inhibitor–induced cutaneous reactions is not unanticipated in …
use of the EGFR inhibitors and the high incidence of cutaneous reactions, our understanding …

… BRAF inhibitors can lead to rash and development of cutaneous keratinocytic neoplasias
for … inhibitors induce similar skin toxicities to EGFR inhibitors such as papulopustular rashes, …

… , the most common adverse events of the EGFR inhibitors are rash and diarrhea, which are
the … and management of EGFR-TKI–related adverse events such as rash and diarrhea should …

… The selectivity and reversibility for EGFR inhibition by the currently … rash. This strategy is
predicated on the hypothesis that inhibition of EGFR in skin correlates with inhibition of EGFR …

… severity rash from EGFR inhibitors [27]. … rashes are dose dependent [29]. Therefore, gradual
dose increment until the skin eruptions appears is a strategy to maximize efficacy of EGFR …

… EGFR TKIs for NSCLC. Erlotinib and gefitinib are reversible EGFR inhibitors that bind to both
wild-type and mutant EGFR, … binds to wild-type and mutant EGFR, as well as to the ErbB …